Valeant Pharma (VRX) Receives Two Additional FTC Requests for Info in Dermatology Acquisitions
Tweet
Share
E-mail
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) has received two separate requests for additional information from the Federal Trade Commission in connection with Valeant's pending Dermik and Ortho Dermatologics acquisitions.
Valeant continues to expect that both the Dermik and Ortho Dermatologics transactions will close by the end of the year and prior to the termination date set forth in the related acquisition agreement.
Valeant continues to expect that both the Dermik and Ortho Dermatologics transactions will close by the end of the year and prior to the termination date set forth in the related acquisition agreement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Holcim to acquire Fermacell from James Hardie for EUR 840M
- Veeva Systems names Dan Rizzo EVP of sales amid leadership change
- Real and RE/MAX Holdings set Aug. 24 merger closing date
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
